Goldman Sachs raises its rating on Laboratory Corp of America Holdings LH from Sell to Neutral and raises its price target from $79 to $86.
Goldman Sachs comments, "We upgrade shares of LH to Neutral from Sell and our 6-month $86 price target now implies 7.1% downside. Our upgrade is based on the following three points (1) a stable volume outlook, (2) strong FCF generation and balance sheet stability, (3) limited-to-zero exposure to ex-US macro uncertainty. As a result, we see a more balanced risk/reward for LH shares at this time. Since adding LH to the Sell List on 12/14/11, the shares are +14% vs. the S&P 500 +12% given better-than-expected volumes. Over the past 12 months, LH is -3% vs. the S&P 500 +4%."
LH closed at $92.61 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorUpgradesPrice TargetIntraday UpdateAnalyst RatingsGoldman SachsHealth CareHealth Care Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in